Title - National Investigation of Cardiovascular Complications in мetaAbolic syndrome

Brief Title - NICA

 

Cross-sectional observational study

 

 

Principal Investigator -  Shlyakhto EV

Scientific Committee - Shlyakhto EV (chairman). Nedogoda S.V.,

 

Simonova G.I., Konradi A.O.

 

Executive  Committee

 

Nedoshovin A.O.

 

Baranova E.I.

 

Turina T.V., Bolshakova O.O., Yemelyanov I.V., Zvartau N.E., Zelninova T.A., Paskar N.A., Poznyakov Yu.M.

 

 

Ethic Committee

 

Kuleshova E.V., Moroshkin

 

 

Observational Committee

 

 

Statistics. Bondarenko B.B., Solntsev VN, Bart VA.

 

 

Introduction

 

Despite long-term investigations of the metabolic syndrome (MS) and practical implementation of this term no standard definition of the syndrome is accepted and data of its independent prognostic value are controversial. Nowadays, epidemiology of the syndrome is well studied in West Europe and USA, while data obtained in other regions, in particular in Russian Federation are limited. The prognostic value of MS in Russian population is unknown and the diagnostic criteria specific for the population are not defined. At the same time, regional heterogeneity of risk factors is obvious and can be explained by genetics actors, national features of nutrition, and other behavior factors. Therefore, national study of MS epidemiology and prognostic significance is actual.

 

 

 

Primary Objective: to study epidemiology of risk factors included in MS in Russian Federation, its prognostic value.

 

 

Secondary objectives

 

    1. To test impact of different definitions in the epidemiology of MS in Russian Federation and select better criteria according to prognostic value

 

    1. To study epidemiology of metabolic syndrome in different regions and ethnic groups in Russian Federation

 

 

 

Study population

 

 

30 regions of Russian Federation (cities with a population over 500 thousand)

 

A random sample of 1000 individuals from each region will be examined.

 

 

Inclusion criteria

 

25-75 years (sex and age stratified sample)

 

Signed informed consent

 

 

 

Study design

 

 

The study will consist of 3 phases

 

 

Phase 1

 

NICA 1

 

Cross-sectional population study of the prevalence of MS and its components in Russian Federation

 

Sample size – 30 000

 

Studying parameters

 

-         questionnaires

 

-         height, weight, BMI, waist circumference, hip circumference, neck circumference

 

-         fasting blood sampling (glucose, total cholesterol, TG, HDLP) + genetics

 

-         seating blood pressure (mean value from 3 measurements on right arm)

 

 

 

Phase 2

 

Instrumental and laboratory examination of patients with risk factors (clinical study)

 

 

Selection criteria (one ore more of the following)

 

 

    1. BP ≥ 130/85 mm Hg

 

    1. Waist circumference ≥80 sm in females and ≥ 94 in males and/or BMI ≥25 kg/m2

 

    1. Dyslipidemia (elevated TG (1,7 mmol/l and/or decreased level of HDLP or therapy for high triglyceride level)

 

    1. fasting glucose ≥5,6 mmol/l

 

Exclusion criteria

 

Associated clinical conditions (stroke, TIA,  IHD, MI, heart failure, renal disease, diabetes mellitus)

 

Severe concomitant diseases (cancer, liver, kidney)

 

 

 

 

List of  laboratory tests OGTT

 

Microalbumiuria

 

HGlA1C

 

CRP, leptin, adiponectin, insulin (fasting and 2 hour ORTT). homocystein levels

 

Thyroid hormone levels

 

Genetic studies (to be discussed)

 

Lipid profile

 

 

List of instrumental tests Echocardiography

 

    • Carotid artery ultrasound (IMT)

 

    • Pulse wave velocity, arterial stiffness and augmentation index (in selected sites)

 

    • Heart rate variability indexes (in selected sites)

 

    • Home blood pressure measurement (4 times per day 2 days)

 

    • Holter monitoring and ABPM

 

    • Densitometry (in selected sites)

 

    • MRI of visceral fat (in selected sites)

 

    • Screening test for obstructive sleep apnea (in selected sites)

 

 

 

 

Questionnaires

 

 

 

    • Sleep apnea

 

    • Depression and anxiety scale

 

    • Cognitive dysfunction (MMSE)

 

    • Quality of life (SF36).

 

Phase 3

 

Observation (prognosis)

 

End-point registration

 

Therapy registration

 

 

 

End-point registration

 

Primary – combined cardiovascular endpoint (cardiovascular death, stroke, MI)

 

Secondary

 

Fatal and nonfatal stroke

 

MI

 

Cardiovascular death

 

Total mortality

 

Diabetes mellitus

 

Heart failure

 

CAD documented

 

Revascularization

 

EDRD